AC ImmuneACIU
ACIU
About: AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Employees: 172
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,957% more call options, than puts
Call options by funds: $144K | Put options by funds: $7K
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
5% more funds holding
Funds holding: 43 [Q3] → 45 (+2) [Q4]
0.84% less ownership
Funds ownership: 28.3% [Q3] → 27.46% (-0.84%) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
31% less capital invested
Capital invested by funds: $107M [Q3] → $73.9M (-$32.7M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$16
662%
upside
Avg. target
$16
662%
upside
High target
$16
662%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 114 / 357 met price target | 662%upside $16 | Buy Reiterated | 14 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ACIU published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer's disease (AD) and DS expected in 2025 Enrollment progress in JNJ-2056 (ACI-35.030) ReTain Phase 2b trial in preclinical AD patients triggered second milestone payment of CHF 24.6 million; JNJ-2056 granted U.S. FDA Fast Track Designation in AD ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety and immunogenicity results in Parkinson's disease (PD); further interim results in H1 2025 Cash resources of CHF 165.5 million at year end provides funding into Q1 2027, assuming no other milestones Lausanne, Switzerland, March 13, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2024, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We significantly advanced our leading position in the precision prevention of neurodegenerative diseases in 2024 through strong pipeline progress and the closing of a landmark deal with Takeda.
Positive
Zacks Investment Research
2 weeks ago
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
2 weeks ago
New Strong Buy Stocks for March 5th
PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025.
Positive
Zacks Investment Research
1 month ago
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for January 31st
ENS, SOPA, MC, SFIX and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
Positive
Benzinga
4 months ago
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson's disease.
Neutral
Zacks Investment Research
7 months ago
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.42. This compares to loss of $0.22 per share a year ago.
Neutral
GlobeNewsWire
7 months ago
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
Positive
Seeking Alpha
7 months ago
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024. The global Alzheimer's therapeutics market size is expected to surpass $8.18 billion by 2032.
Neutral
GlobeNewsWire
7 months ago
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its active-immunotherapy candidate, ACI-35.030 (now called JNJ-2056), targeting the pathologic form of the Tau protein, phosphorylated Tau (pTau), has received Fast Track designation from the U.S. Food and Drug Administration (FDA). The recently initiated Phase 2b clinical trial ReTain is currently recruiting participants with preclinical Alzheimer's disease, where individuals have yet to show clinical symptoms.
Charts implemented using Lightweight Charts™